Itraconazole

Generic Name
Itraconazole
Brand Names
Sporanox, Tolsura
Drug Type
Small Molecule
Chemical Formula
C35H38Cl2N8O4
CAS Number
84625-61-6
Unique Ingredient Identifier
304NUG5GF4
Background

One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions
Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
Associated Therapies
-
Clinical Trials
Related News

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
64
Registration Number
NCT06732388
Locations
🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 4 locations

A Study of the Effect of Itraconazole and Phenytoin on MK-1084 in Healthy Adults (MK-1084-008)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: MK-1084
Drug: Itraconazole
Drug: Phenytoin
First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT06719557
Locations
🇺🇸

Celerion (Site 0001), Lincoln, Nebraska, United States

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Phase 1
Not yet recruiting
Conditions
Advanced Breast Cancer
Interventions
Drug: SHR-A1811
Drug: Ritonavir
Drug: Itraconazole
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
32
Registration Number
NCT06710990
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

A Study to Learn if the Study Medicine Called Itraconazole Changes How the Body Processes the Other Study Medicine Called PF-07258669 In Older Adults

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
Drug: PF-07258669
Drug: Itraconazole
First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT06706869

Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults

First Posted Date
2024-11-22
Last Posted Date
2024-11-22
Lead Sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Target Recruit Count
16
Registration Number
NCT06701136

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
AbbVie
Target Recruit Count
112
Registration Number
NCT06698926
Locations
🇺🇸

Acpru /Id# 270532, Grayslake, Illinois, United States

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
Drug: Divarasib
Drug: Itraconazole
First Posted Date
2024-11-15
Last Posted Date
2024-12-16
Lead Sponsor
Genentech, Inc.
Target Recruit Count
18
Registration Number
NCT06690138
Locations
🇺🇸

Dallas Clinical Research Unit, Dallas, Texas, United States

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Nemtabrutinib
Drug: Itraconazole
First Posted Date
2024-11-14
Last Posted Date
2024-11-14
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT06688045
Locations
🇺🇸

Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States

A Study to Investigate the Pharmacokinetics of AZD0780 When Administered Alone and in Combination With Itraconazole and Carbamazepine in Healthy Participants Aged 18 to 75 Years of Age

First Posted Date
2024-11-04
Last Posted Date
2024-11-04
Lead Sponsor
AstraZeneca
Target Recruit Count
42
Registration Number
NCT06671405
Locations
🇺🇸

Research Site, Brooklyn, Maryland, United States

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK3923868
Drug: Itraconazole
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT06597500
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy